

## **Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors.**

Amy D. Hanna, Marie Janczura, Eric Cho, Angela F. Dulhunty\* and  
Nicole A. Beard\*

John Curtin School of Medical Research, Australian Capital Territory, Australia, 0200

**Running title:** Daunorubicin and cardiac ryanodine receptors.

**Corresponding Author:**

Prof AF. Dulhunty  
John Curtin School of Medical Research  
Australian National University,  
PO Box 334,  
Canberra, ACT 2601  
Australia

Telephone +61 2 6125 4491  
Fax +61 2 6125 4761  
Email angela.dulhunty@anu.edu.au

<b>Number of text pages:</b>	
<b>Number of tables:</b>	<b>2</b>
<b>Number of figures:</b>	<b>8</b>
<b>Number of references:</b>	<b>49</b>
<b>Number of words in the Abstract</b>	<b>244</b>
<b>Number of words in the Introduction</b>	<b>765</b>
<b>Number of words in the Discussion</b>	<b>1378</b>

**NON-STANDARD ABBREVIATIONS.**

CSQ1 – skeletal isoform of calsequestrin; calsequestrin type 1  
CSQ2 – cardiac isoform of calsequestrin; calsequestrin type 2.  
DAD – delayed after depolarization  
EAD – early after depolarization  
 $I_F$  – fractional mean current  
NHMRC – National Health and Medical Research Council  
 $P_o$  – open probability  
RyR1 – skeletal isoform of the ryanodine receptor; ryanodine receptor type 1  
RyR2 – cardiac isoform of the ryanodine receptor; ryanodine receptor type 2  
SR – sarcoplasmic reticulum

## ABSTRACT

Our aim was to examine the molecular basis for acute effects of the anthracycline daunorubicin on cardiac ryanodine receptor (RyR2) channels and cardiac calsequestrin (CSQ2). Cardiotoxic effects of anthracyclines preclude their chemotherapeutic use in patients with pre-existing heart conditions. To address this significant problem the mechanisms of anthracycline toxicity must be defined, but at present are poorly understood. RyR2 channel activity was assessed by measuring  $\text{Ca}^{2+}$  release from cardiac sarcoplasmic reticulum vesicles and by examining single RyR2 channels inserted into artificial lipid bilayers. We show that 0.5 to 10  $\mu\text{M}$  daunorubicin increases the activity of RyR2 channels after 5 to 10 min and that activity then declines to very low levels when channels are exposed daunorubicin concentrations of  $\geq 2.5 \mu\text{M}$  for a further 10 to 20 min. Extensive dissection of these effects shows for the first time that the activation results from a redox-independent binding of daunorubicin to the RyR2 complex. Novel data includes the demonstration of daunorubicin binding to RyR2. We provide compelling evidence that RyR2 channel inhibition is due to the oxidation of free SH groups. The oxidation reaction is prevented by the presence of 1 mM dithiothreitol (DTT). We also present novel data showing that CSQ2 modifies the response of RyR2 to daunorubicin, but that the response of RyR2 is not dependent on daunorubicin binding to CSQ2. We suggest that binding of daunorubicin to RyR2 and CSQ2, and oxidation of RyR2, are all likely to contribute to anthracycline-induced cardiotoxicity during chemotherapy.

## **INTRODUCTION**

Cardiac and skeletal muscle contraction is triggered by excitation-contraction (EC) coupling, the process which links depolarization of the surface membrane with  $\text{Ca}^{2+}$  release from the internal sarcoplasmic reticulum (SR)  $\text{Ca}^{2+}$  store.  $\text{Ca}^{2+}$  is released from the SR through the ryanodine receptor (RyR)  $\text{Ca}^{2+}$  channel which forms the hub of a macromolecular complex that spans the SR membrane and includes cytoplasmic proteins and proteins in the lumen of the SR. The efficacy of  $\text{Ca}^{2+}$  release is set by the integrated effects on RyR channel activity of associated proteins/ligands, covalent modification by redox reactions and phosphorylation and by ionic conditions. In the heart, single point mutations in the cardiac isoform of the RyR (RyR2) or the calcium binding protein calsequestrin (CSQ2, located within the lumen of the junctional SR) lead to ventricular tachycardia and sudden death (Brini, 2004; Lahat et al., 2001), while therapeutic drugs such as the anthracyclines can seriously disrupt RyR2 function.

Anthracyclines, including daunorubicin and doxorubicin are highly effective in the treatment of a variety of cancers. The drugs have a long half-life, accumulate in the heart at concentrations in the nM and low  $\mu\text{M}$  range and induce an ~8-fold increase in the risk of death due to cardiac complications (Mertens et al., 2001). The cardiac complications manifest as acute arrhythmias and hypotension and chronic conditions such as dilated cardiomyopathy and congestive heart failure (Menna et al., 2007). The cardiotoxicity is thought to result from the synergistic actions of the acute and chronic effects of the drugs on SR proteins. The acute effects are attributed to the accumulated anthracycline binding to target protein(s), while the chronic effects include changes in expression of  $\text{Ca}^{2+}$  handling proteins such as RyR2, CSQ2 and SERCA (the sarcoplasmic endoplasmic reticulum  $\text{Ca}^{2+}$  ATPase) (Arai et al., 1998; Gambliel et al., 2002).

Anthracycline binding to SR proteins results in reduced SR  $\text{Ca}^{2+}$  storage capacity and modified  $\text{Ca}^{2+}$  release. The anthracyclines cross the surface and SR membranes, bind to CSQ2 (Charlier et al., 2005; Kim et al., 2007; Park et al., 2005) and alter RyR1 and RyR2 activity

(Abramson et al., 1988; Feng et al., 1999; Ondrias et al., 1990; Pessah et al., 1990). Daunorubicin at 2.5 – 10  $\mu\text{M}$  initially activates native RyR2 and then irreversibly inhibits the channels (Ondrias et al., 1990).  $\text{Ca}^{2+}$  release from SR vesicles is inhibited by 1 – 30  $\mu\text{M}$  daunorubicin (Olson et al., 2000).

The mechanism of daunorubicin actions on RyR2 are not well understood and are likely to include redox modification of the protein. Daunorubicin contains a quinone moiety which undergoes redox cycling and induces oxidative tissue damage (Menna et al., 2007). This could alter RyR2 activity by decreasing the number of reactive thiol groups, either by oxidizing free -SH groups to disulphides (Abramson et al., 1988), or by transiently withdrawing electrons and shifting the redox potential of reactive thiols to more negative values (Marinov et al., 2007; Pessah et al., 2002). The RyR2 monomer contains 89 cysteine residues, 21 of which are available for oxidation with functional consequences. Doxorubicin reduces the number of free thiols on RyR1 (Feng et al., 1999). The contribution of redox modifications to anthracycline action on RyR2 remains controversial. The thiol-reducing agent, dithiothreitol (DTT) prevents doxorubicin-induced inhibition of RyR2 channels (Ondrias et al., 1990), but not inhibition of  $\text{Ca}^{2+}$  release from the SR (Olson et al., 2000). The ability of daunorubicin to bind to RyR2 and directly modify channel gating has not previously been reported and is examined here.

CSQ2 is a second SR anthracycline target. Anthracyclines bind to CSQ2 with micromolar affinity (Kim et al., 2005), altering its  $\text{Ca}^{2+}$  binding capacity. Given that CSQ2 is a regulator of RyR2 (Wei et al., 2009), anthracyclines might impact SR  $\text{Ca}^{2+}$  homeostasis through modifying CSQ2 and its interaction with RyR2. There have been few studies of the effects of anthracyclines on single RyR2 channel activity. Most studies have used cardiac SR  $\text{Ca}^{2+}$  release or [ $^3\text{H}$ ]ryanodine binding as an index of RyR2 channel function, but not the molecular mechanism of drug action on RyR2 channel activity. The possibility that CSQ2 may influence the action of anthracyclines on RyR2 channel function has not previously been investigated.

In this manuscript we examine the actions of daunorubicin on  $\text{Ca}^{2+}$  release from cardiac SR vesicles and on the activity of single RyR2 channels in lipid bilayers. We explore the possibility that the action of the drug is due to redox modification of reactive thiols on the RyR2 complex, or to redox-independent ligand binding. We examine the effect of daunorubicin on the  $\text{Ca}^{2+}$  binding capacity of CSQ2 and whether this contributes to the anthracycline effects on RyR2 channel activity.

## **MATERIALS AND METHODS**

*Materials.* The monoclonal anti-RyR antibody was obtained from Abcam (Cambridge, United Kingdom). Phospholipids were obtained from Avanti Polar Lipids (Alabama, United States). All other chemicals were obtained from Sigma-Aldrich (Castle Hill, Australia).

*SR vesicle isolation, RyR2 and CSQ2 purification.* Cardiac SR vesicles were prepared from sheep heart (Laver et al., 1995). RyRs were solublized and purified from SR as described by (Dulhunty et al., 2005). CSQ2 isolated from cardiac SR was purified by gel elution (Beard et al., 2008). CSQ2 was eluted from large vertical slab SDS polyacrylamide gels in a denaturing buffer using an 8.5% resolving gel (containing 8.5% acrylamide/bis (29:1), 0.375 M Tris-HCl (pH 8.8), 0.1% SDS, 0.05% APS, and 0.1% TEMED) and a 4% stacking gel consisting of 4% acrylamide/bis (29:1), 0.125 M Tris-HCl, pH 6.8, 0.1% SDS 0.05% APS and 0.1% TEMED. SDS-PAGE and Western Blot are described in (Beard et al., 2002). The Ca<sup>2+</sup> binding capacity of CSQ2 was determined using a <sup>45</sup>Ca<sup>2+</sup> spin dialysis binding assay (Maruyama et al., 1984).

*Single channel recording and analysis.* Planar bilayers separating two baths (*cis* and *trans*) were formed as previously described (Beard et al., 2005; Beard et al., 2002). SR vesicles (50 µg) were added to the *cis* solution so that the cytoplasmic surface of the SR and RyRs faced the *cis* solution after incorporation into the lipid bilayer. For vesicle incorporation, the solution compositions were: *cis*: 230 mM CsMS, 20 mM CsCl, 1 mM CaCl<sub>2</sub>, and 10 mM TES (pH 7.4); and *trans*: 30 mM CsMS, 20 mM CsCl, 1 mM CaCl<sub>2</sub>, and 10 mM TES (pH 7.4). After incorporation of a channel, *trans* [Cs<sup>+</sup>] was raised to 250 mM with addition of 200 mM CsMS and the *cis* solution was altered by the addition 1.32mM BAPTA (free [Ca<sup>2+</sup>] = 1 µM). In some experiments, endogenous CSQ2 was dissociated from the RyR/triadin/junctin complex by exposure to a high ionic strength solution (Beard et al., 2002). Triadin and junctin are transmembrane proteins that bind to the luminal domain of RyR2. CSQ2 associates with the RyR2/triadin/junctin complex by binding to junctin and triadin (Gyorke and Terentyev, 2008; Wei et al., 2009). Electrical

potentials are expressed here as cytoplasmic relative to luminal. The luminal solution was maintained at virtual ground. Single channel currents were recorded at +40 mV and -40 mV. The data was filtered at 1 kHz and sampled at 5 kHz. The mean open times of channels varies from 1 ms to 10 ms and the measured dead times for the filter/s (using a 20% discriminator), was <200  $\mu$ s and the dead time calculated for an ideal 4<sup>th</sup> order low pass bessel filter (as in the Axopatch 200A) is no more than 200  $\mu$ s. Thus missed events would have been few and would not have altered the average parameters (Beard et al., 2008). Single channel parameters were obtained using the Channel 2 program (developed by P.W. Gage and M. Smith, John Curtin School of Medical Research, Canberra, Australia) from 60 to 180 s of channel activity. Open probability ( $P_o$ ) was measured as fractional mean current ( $I'_F$ ) or as the fraction of time that the channel was open using threshold discriminators.  $I'_F$  is the average of all data points in a recording period, divided by the maximum single channel current.  $I'_F$  is approximately equal to the  $P_o$  measured by threshold discrimination. Experiments were performed at  $23 \pm 2$  °C.

*Calcium release assay.* A Cary 3 spectrophotometer was used to monitor extravesicular  $\text{Ca}^{2+}$  at 710 nm, using the  $\text{Ca}^{2+}$  indicator antipyrylazo III (Dulhunty et al., 1999; Jalilian et al., 2008). Cardiac SR vesicles (200  $\mu$ g/ml) were added to a solution containing 100 mM  $\text{KH}_2\text{PO}_4$ , 0.4 mM antipyrylazo III, 1 mM  $\text{Na}_2\text{ATP}$  and 4 mM  $\text{MgCl}_2$  with temperature controlled at 25 °C. The cuvette solution was magnetically stirred throughout the experiment. Cardiac SR vesicles were added to the cuvette and the  $\text{Ca}^{2+}$  ATPase was activated by MgATP in the solution. The SR was loaded with four additions of 7.5  $\mu$ M  $\text{Ca}^{2+}$ . Thapsigargin (300 nM) was added to block the  $\text{Ca}^{2+}$ -ATPase (Sagara and Inesi, 1991), so that  $\text{Ca}^{2+}$  release could be specifically measured. Ruthenium red was then added to confirm that  $\text{Ca}^{2+}$  release was through the RyR and finally  $\text{Ca}^{2+}$  ionophore (A23187) was added to release  $\text{Ca}^{2+}$  remaining in the SR. In one series of experiments daunorubicin was added 30 s after thapsigargin (Fig. 1A), to examine the ability of high concentrations of the drug to immediately stimulate  $\text{Ca}^{2+}$  release. In a second series, SR vesicles



were incubated for 20 min with daunorubicin (or with vehicle buffer alone for control experiments) before they were added to the cuvette. The concentration of daunorubicin or vehicle buffer in the cuvette was adjusted to the incubation concentration and the vesicles loaded with  $\text{Ca}^{2+}$  in the usual way.  $\text{Ca}^{2+}$  release in this experiment was stimulated by 5 mM caffeine, following addition of thapsigargin (Fig. 1B). Calibration curves of optical density changes with addition of 12.5  $\mu\text{M}$  to 50  $\mu\text{M}$   $\text{CaCl}_2$  to the cuvette solution showed that neither daunorubicin, caffeine nor ruthenium red affected the calibration. The initial rate of daunorubicin or caffeine induced  $\text{Ca}^{2+}$  release was measured. The total amount of  $\text{Ca}^{2+}$  loaded into the SR was not altered by incubation of SR vesicles with daunorubicin.

*Statistics.* Average data are given as mean  $\pm$ SEM. Statistical significance was evaluated using paired or unpaired Student's t-test as appropriate or ANOVA. Numbers of observations (n) are given in Tables and Figure legends. RyR channel activity is notoriously variable, possibly because of differences between channels in the degree phosphorylation, nitrosylation or oxidation (Copello et al., 1997; Marengo et al., 1998). To reduce effects of variability in control open probability ( $P_{oC}$ ), and to evaluate parameters after daunorubicin addition ( $P_{oD}$ ) or NEM addition ( $P_{oN}$ ), data are expressed as the difference between the  $\log_{10} P_{oC}$  and  $\log_{10} P_{oD}$  or  $P_{oN}$  for each channel (eg  $\log_{10} P_{oC} - \log_{10} P_{oD}$ ). The difference from control was assessed with a paired t-test applied to  $\log_{10} P_{oC}$ ,  $\log_{10} P_{oD}$  or  $\log_{10} P_{oN}$ . The difference between relative data obtained at different times or concentrations was assessed using ANOVA with the multidimensional Mahalanobis test. A  $P$  value of  $<0.05$  was considered significant for all tests.

*Daunorubicin coupled CNBr-activated Sepharose.* Daunorubicin was coupled to CNBr-activated Sepharose 4B following manufacturer's instructions. Purified RyR2 (0.5 mg/ml) in 50 mM Tris-HCl, pH 8 was incubated with the mixture with rotation overnight at 4° C. Unbound RyR2 was removed by washing with 50mM Tris-HCl, pH 8. Proteins bound to the daunorubicin coupled CNBr-activated Sepharose 4B were eluted by boiling for 1 min in sample buffer (0.05 M Tris-

HCl (pH 6.8), 2% SDS, 0.01 M EDTA, 10% glycerol, 0.6 M mercaptoethanol , 0.02% bromophenolblue) and 0.15% Triton-X 100. The resultant supernatant was loaded on 4-12% SDS Page gels, transferred and probed with an anti RyR2 antibody (34C). In one experiment, non-specific binding sites on RyR2 were saturated by preincubating purified RyR2 with activated Sepharose for 2 h at 4° C with rotation prior to their addition to daunorubicin-coupled sepharose.

## **RESULTS**

*Ca<sup>2+</sup> release from cardiac SR vesicles.* The records of full experiments are shown in Fig. 1.

There were no consistent differences between the amounts of Ca<sup>2+</sup> taken up into the SR when was daunorubicin was added after (Fig. 1A) or before (Fig. 1B) store loading. This is indicated by the vertical arrows at the end of each record in Fig. 1. The height of the arrow indicates the total Ca<sup>2+</sup> released after thapsigargin addition, by daunorubicin or caffeine and then by the ionophore. The amount released is equal to the amount taken up and stored and is similar in the two types of experiment. To demonstrate that daunorubicin interacted with the Ca<sup>2+</sup> release mechanism in our hands, we examined the immediate effect of the drug on Ca<sup>2+</sup> release using concentrations  $\geq 10$   $\mu\text{M}$  (Fig. 2A). The drug concentrations used to stimulate immediate Ca<sup>2+</sup> release were higher than those required to activate release after longer incubations in subsequent studies with SR vesicles and single RyR2 channels, and higher than clinical concentrations. This was expected as the activation by lower concentrations takes several minutes to develop (see Fig. 3 below). The initial rate of Ca<sup>2+</sup> release increased in a concentration-dependent manner to rates of  $\sim 120$  nmoles/mg/min with 500  $\mu\text{M}$  daunorubicin (Fig. 2B, upper trace). The release was through RyR2 as it was blocked by ruthenium red. When the rate was measured 10 min after addition of 10  $\mu\text{M}$  daunorubicin, there was a significant increase in Ca<sup>2+</sup> release rate, in contrast to the initial rate (measured within 10 s of daunorubicin addition) which was not changed (insert Fig. 2B).

The effect of longer exposure to daunorubicin was examined by incubating vesicles with daunorubicin for 20 min before Ca<sup>2+</sup> uptake was initiated and  $\sim 30$  min before Ca<sup>2+</sup> release was examined. Although the rate of Ca<sup>2+</sup> release after thapsigargin addition was low, there was a trend towards an increase in release after addition of 5 – 10 nM daunorubicin and a significant decrease seen with 10  $\mu\text{M}$  daunorubicin. To more accurately measure Ca<sup>2+</sup> release, a stronger release was initiated with caffeine (Fig 1B and 2C-E). The rate of caffeine-induced Ca<sup>2+</sup> release, measured  $\sim 30$  min after initial exposure to daunorubicin, increased significantly with only 5 nM

and 10 nM of the drug, then declined towards control levels as the concentration increased to 50 nM and was significantly depressed with 10  $\mu$ M (Fig. 2C-E). The drug concentrations required to alter  $\text{Ca}^{2+}$  release during prolonged exposures were similar to those required to alter channel activity during exposure lasting several minutes (following section). The  $\text{Ca}^{2+}$  release experiments show that daunorubicin either stimulated or inhibited  $\text{Ca}^{2+}$  release depending on the concentration and the duration of exposure to the drug.

*RyR2 channels in lipid bilayers.* Daunorubicin was added to the luminal (*trans*) solution bathing RyR2 channels in lipid bilayers. Daunorubicin concentrations of 500 nM and 1  $\mu$ M increased RyR2 activity after several minutes (Fig. 3A&C) and the increased activity was maintained for the duration of exposure to daunorubicin (up to 40min). Activity increased more rapidly with higher drug concentrations (compare the rates of change in  $P_o$  during exposure to 1  $\mu$ M and 2.5  $\mu$ M daunorubicin (Fig. 3C&D) and average data in Table 1). With higher drug concentrations (2.5  $\mu$ M and 10  $\mu$ M), activity first increased and then declined (Fig. 3B&D), to levels which were significantly less than the maximum activity and less than that before daunorubicin addition. The very low activity was maintained for lifetime of the experiment (up to 60 min). The activity of the channel in Fig. 3C was enhanced between 7.5 and 20 min exposure to 1  $\mu$ M daunorubicin and then declined after 20 min to levels that were less than the maximum, but higher than before drug addition. This fall in activity may reflect a slow onset inhibition with 1  $\mu$ M daunorubicin. We apply the term “activation phase” to the period within ~3-8 min after daunorubicin application when  $P_o$  was first enhanced compared to preceding “control” levels before drug application and the term “inhibitory phase” as periods between ~11 and 13 min with  $\geq 2.5 \mu\text{M}$  when  $P_o$  was depressed compared to initial levels.

Channel open probability ( $P_o$ ) with daunorubicin ( $P_{oD}$ ) relative to the control ( $P_{oC}$ , before drug addition) for each channel was calculated and average relative  $P_o$  increased significantly

after incubations with  $\geq 500$  nM daunorubicin (Fig. 3E). Concentrations  $> 1$   $\mu$ M produced a significant inhibition at longer times. The relative  $P_o$  during the inhibition phase was significantly lower than the previously activated  $P_o$ , and significantly lower than control activity (Fig. 3F). The channels remained inhibited for the lifetime of the bilayer (Fig. 3D).

*Reversibility of daunorubicin-induced activation and inhibition.* To determine if the effects of daunorubicin on RyR2 were reversible, we examined the effect of perfusing the *trans* chamber with *trans* solution lacking daunorubicin. Disulphide formation cannot be reversed by removing the oxidizing reagent, although it can be reversed by addition of reducing reagents. Thus recovery after perfusion of the *trans* chamber (removal of daunorubicin) would indicate that the effect had not been due to oxidation of free –SH groups to –S-S- moieties. We found that perfusion after activation by 1  $\mu$ M daunorubicin was followed (after  $4.0 \pm 0.8$  min) by a reduction in channel activity to control levels that were maintained for the duration of the experiment (Fig. 4A&B). This washout reversibility suggested that the increase in activity was likely to be due either to the drug binding to RyR2 or to transient redistribution of electrons in the presence of the drug without chemical modification (Marinov et al., 2007), as opposed to the oxidation of free –SH groups to form a -S-S-. Many non-thiol reagents have a redox potential and can also alter RyR2 function by electron redistribution within free -SH groups without making or breaking disulphide bonds (Marinov et al., 2007; Pessah et al., 2002). The effects of electron redistribution are reversed by removing the agents or by adding oxidizing or reducing reagents to normalize the redox potential of the environment surrounding the free –SH group. The washout experiments do not distinguish between cytoplasmic, transmembrane or luminal binding/modification sites because daunorubicin is lipid soluble and equilibrates across the bilayer and could therefore bind to sites located on the luminal, intramembrane or cytoplasmic face of the RyR2 complex. Daunorubicin would re-equilibrate across the bilayer after perfusion of the *trans* chamber and the concentration in the lipid and cytoplasmic compartments would be similarly reduced.

To determine whether daunorubicin increased RyR2 activity by binding to the protein or by causing a transient redistribution of electrons, we examined drug binding to RyR2.

Daunorubicin was coupled to CNBr-activated sepharose and incubated with purified RyR2. The eluate was electrophoresed and following western blot the RyR2 was detected with an anti-RyR antibody. The strong immunostaining (Fig. 4E) indicated that daunorubicin bound specifically to the RyR2 protein. After preincubating RyR2 with CNBr-activated sepharose to eliminate non-specific binding, the RyR2 bound strongly to the daunorubicin coupled CNBr-activated sepharose (data not shown). RyR2 did not bind to activated sepharose in the absence of daunorubicin (Fig. 4E).

In contrast to daunorubicin-induced activation, inhibition by 2.5  $\mu$ M daunorubicin was not relieved by perfusion of the *trans* chamber (Fig. 4C&D). Thus daunorubicin-induced inhibition is likely to be due to either a chemical modification such as oxidation of free –SH groups to –S-S- bonds, which cannot be reversed (reduced) simply by drug removal, or to ligand binding to a high affinity site or an inaccessible site that becomes buried after binding.

*DTT protection of free –SH groups and reduction of -S-S-*. The potential role of –SH modification was examined using DTT, a strong reducing agent used to protect free thiols from oxidation to –S-S- groups and from electron withdrawal, or to reduce –S-S- bonds (Cleland, 1964; Eager et al., 1997). Prevention or reversal of either activation or inhibition by DTT would indicate effects due to redox modification of free thiol groups. DTT at 1 mM prevents RyR2 oxidation (Eager and Dulhunty, 1999; Eager et al., 1997) and its addition to the *cis* or *trans* chamber can indicate the location of the reactive –SH groups as DTT is not highly lipid soluble at pH 7.4 and does not cross the bilayer in significant amounts. Since the thiol groups of DTT have pKa values of 9.1 and 10.2 (Zhang et al., 1991) and the pH of the bilayer solutions was buffered

to 7.4, DTT would be predominantly in its water soluble, ionized form (White, 1999) and would be unable to easily cross the lipid bilayer (Rang, 2007; White, 1999).

*DTT in the trans solution.* DTT (1 mM) added to the *trans* solution before 10  $\mu$ M daunorubicin (Fig 5A&B) did not alter RyR2 activity or prevent the usual increase and then decrease in channel activity. Similarly, 1 mM DTT added to the *trans* chamber after daunorubicin-induced inhibition did not reverse the inhibition (Fig. 5C&D). Therefore, if -SH groups are modified to alter RyR2 activity, they are not located on the SR luminal side of the RyR2 complex.

*DTT in the cis solution.* DTT in the *cis* solution did not alter activation by 10  $\mu$ M daunorubicin, but did prevent the inhibitory action of the drug (Fig. 6A). Channel activity increased and remained greater than control for up to 25 min after 10  $\mu$ M daunorubicin addition (Fig. 6B). This result suggests that the inhibitory effect of daunorubicin is caused by oxidation of free thiol groups on the cytoplasmic domain of the RyR2 complex. The persistence of activation with DTT in the *cis* or the *trans* solution indicated that activation was not due either to oxidation of free -SH groups to -S-S- or to electron withdrawal effects. Surprisingly, channel activity remained at very low values when DTT was added to the *cis* chamber after inhibition by 10  $\mu$ M daunorubicin (Fig. 6C&D), indicating that DTT did not reverse inhibition once it had been established. This apparent contradiction might be explained if the -S-S- became buried in the protein after its formation and were not accessible to DTT (see Discussion).

*N-Ethylmaleimide (NEM) probe for modification of free sulphydryl groups.* The results thus far show two actions of daunorubicin on the RyR2 channel complex. Firstly, an activation that is not dependent on redox modification and is most likely the consequence of a direct interaction between daunorubicin and the RyR2 complex. The second delayed inhibitory effect appears to be redox sensitive in that it can be prevented if DTT is present in the cytoplasmic solution before

daunorubicin is added. To further explore the involvement of free –SH groups, we modified (alkylated) free –SH groups on the RyR2 complex with NEM before adding daunorubicin.

NEM alone influenced RyR2 channel activity.  $P_o$  fell progressively for 30 min following addition of 10 mM NEM to the *cis* solution (Fig. 7A). NEM is highly lipid soluble (Abbott and Schachter, 1976) and presumably equilibrated across the bilayer to alkylate –SH groups on luminal, cytoplasmic and transmembrane parts of the RyR2 complex. When 10  $\mu$ M daunorubicin was added ~9 min after NEM (Fig. 7B), the decline in activity seen with NEM alone appeared to be halted. Channel activity remained less than control, but did not decline to levels seen with exposure to NEM alone (Fig. 7A). To evaluate the effect of daunorubicin in the presence of NEM,  $P_o$  with daunorubicin was normalized to  $P_o$  in NEM prior to daunorubicin addition (NEM control) in each channel and average data shown in Fig. 7C. This normalization procedure facilitated interpretation of the effects of daunorubicin alone on the NEM background, by removing the specific effect of NEM. Relative  $P_o$  increased above the NEM control after 10 min and remained greater than the NEM control for the next 20 min. The increase in  $P_o$  was reminiscent of the activation phase seen in the absence of NEM (Figs. 3-6 above).

Relative  $P_o$  during the activation and inhibitory phases following 10  $\mu$ M daunorubicin application in normal and NEM-alkylated channels are compared in Fig. 7D. There is a significant increase in relative  $P_o$  during the activation phase in both cases with no significant difference between the relative increases in activity. The significant fall in  $P_o$  to less than control levels in the inhibition phase in normal channels is not seen in the NEM-modified channels, where relative  $P_o$  in the inhibitory phase was not significantly different from that in the activation phase. There was a trend towards a decline in  $P_o$  (Fig. 7C&7D) which may have been due to a residual inhibitory effect of daunorubicin, but was more likely due to continued NEM action shown in Fig. 7A. Notably, relative  $P_o$  during the inhibitory phase in NEM modified channels did



not fall below the control level recorded before daunorubicin application. The difference between relative  $P_o$  in the normal and NEM-modified channels in the inhibitory phase was significant, thus the normal daunorubicin-induced inhibition appears to have been largely prevented by NEM-alkylation. This is consistent with the possibility that free –SH groups that are normally oxidized by daunorubicin and produce channel inhibition were modified by NEM and no longer available to be oxidized by daunorubicin.

*Influence of CSQ2 on daunorubicin-induced changes in RyR2 activity.* Since anthracyclines bind to CSQ2 (Kim et al., 2005) and CSQ2 modifies RyR2 activity (Wei et al., 2009), the effects of daunorubicin on RyR2 may have been mediated by daunorubicin binding to CSQ2 which remains associated with RyR2 channels when they are incorporated into the bilayer with SR vesicles (Beard et al., 2002; Wei et al., 2009). To determine whether CSQ2 influenced the response of RyR2 to daunorubicin, endogenous CSQ2 was selectively dissociated from the RyR/triadin/junctin complex by exposing the luminal side of native RyR2 channels to a high ionic strength solution (500 mM Cs<sup>+</sup>) following channel incorporation into lipid bilayers (Beard et al., 2002). A decrease in activity associated with CSQ2 dissociation from RyR2 was observed (Wei et al., 2009) and then the *trans* chamber was perfused to remove dissociated CSQ2 and return the ionic strength to the usual 250 mM. The RyR2 channels lacking CSQ2 responded to 2.5 μM daunorubicin in a similar manner to native RyR2s containing CSQ2 (Fig. 8). An initial increase in channel activity (from a  $P_o$  of  $0.06 \pm 0.01$  to  $0.15 \pm 0.03$ ) was followed by a decline in  $P_o$  to  $0.05 \pm 0.01$ . Relative  $P_o$  in the activation phase was similar in normal channels and channels lacking CSQ2 (Fig. 8). Relative  $P_o$  fell significantly in the inhibitory phase in the absence of CSQ2, but was not significantly less than control and was significantly greater than the relative  $P_o$  during the inhibitory phase in normal channels. Thus the absence of CSQ2 reduced the magnitude of daunorubicin-induced inhibition.

Although the absence of CSQ2 had no significant effect on the degree of activation induced by daunorubicin, the time taken to reach maximum activity was significantly longer than in RyR2 channels from which CSQ2 had not been dissociated (Table 1). The time to reach a minimum during the inhibitory phase of daunorubicin action also tended to be longer in the absence of CSQ2, but the change was not statistically significant. These results suggest that daunorubicin's interactions with RyR2 are modulated by CSQ2, but that the interactions do not primarily depend on daunorubicin's association with CSQ2. Daunorubicin's interaction with RyR2 may be modified by changes in the channel induced by CSQ2 binding to triadin and/or junctin.

Daunorubicin could influence  $\text{Ca}^{2+}$  release from cardiac SR by modifying the  $\text{Ca}^{2+}$  binding capacity of CSQ2 and hence the amount of  $\text{Ca}^{2+}$  stored in the SR. We found that 2.5  $\mu\text{M}$  daunorubicin reduced the capacity of CSQ2 for  $\text{Ca}^{2+}$  binding to >70% of that in the absence of the drug at all concentrations of  $\text{Ca}^{2+}$  tested (Table 2). It is not clear from the present experiments how the effects on  $\text{Ca}^{2+}$  binding capacity may translate into alterations in the way CSQ2 regulates  $\text{Ca}^{2+}$  release through RyRs, but is likely to reduce the amount of  $\text{Ca}^{2+}$  available for release during systole.

## DISCUSSION

We show two separate actions of the chemotherapeutic agent daunorubicin on RyR2 channels, with novel observations on the nature, time and concentration dependence of these effects. We show for the first time that daunorubicin-induced activation of RyR2 is not due to redox modification, but likely follows daunorubicin binding to RyR2, which we also directly demonstrated for the first time. The results indicate that the slower inhibitory phase of daunorubicin's action that is mediated by -S-S- formation at a site or sites accessible from the cytoplasmic side of RyR2. Unexpectedly, CSQ2 binding to RyR2 modulates the effects of daunorubicin on the channel, but the effects are not due to daunorubicin binding to CSQ2. However daunorubicin may reduce  $\text{Ca}^{2+}$  release through RyR2 by reducing the  $\text{Ca}^{2+}$  binding capacity of CSQ2 and hence the  $\text{Ca}^{2+}$  load in the SR.

The results do not exclude the possibility that the effects of daunorubicin on RyR2 are mediated by influences of the drug on associated proteins which modulate RyR2 activity, although preliminary data indicates that purified RyR2 channels respond to daunorubicin in the same way as the native channels.

*The activation phase.* The daunorubicin-induced increase in activity was reversed when the drug was removed, which suggested that the increased activity was due either to drug binding or to transient electron redistribution within reactive thiol groups (Marinov et al., 2007; Pessah et al., 2002) as distinct from oxidation of thiols to disulphides (Eager and Dulhunty, 1999). The increase in  $P_o$  was observed more quickly after application at higher daunorubicin concentrations and apparently saturated with 1  $\mu\text{M}$  daunorubicin. The saturation may have been due the onset of inhibition masking further increases in activity. However activity did not increase beyond this maximum when inhibition was prevented either by DTT in the *cis* chamber or by NEM treatment, suggesting that the maximum response was achieved with 1  $\mu\text{M}$  daunorubicin. The activation site could not be identified as being on the cytoplasmic, transmembrane or luminal domain of the

RyR2 complex as the hydrophobic drug would have equilibrated rapidly across the bilayer and could bind to a hydrophobic pocket within the RyR2 protein complex, either within membrane spanning regions, luminal residues or microdomains in the cytoplasmic assembly.

It should be noted oxidation of “exposed” -SH groups by low concentrations of oxidants leads to RyR2 activation. When the oxidant concentration increases, oxidation of less accessible -SH groups leads to inhibition and both activation and inhibition are prevented by DTT (Eager and Dulhunty, 1999; Eager et al., 1997). That we did not see oxidation-induced activation in the present experiments is curious. One possibility is that the anthracyclines bind to RyR2 near the “exposed” SH groups and prevent their oxidation to disulphides, perhaps by sterically hindering the required close interaction between two -SH groups.

*The inhibitory phase.* Inhibition was not reversed by drug washout, indicating that it either depended on oxidation of free -SH groups to -S-S-, or that the inhibition depended on binding which was very high affinity or that the site was inaccessible to the bulk solution. The fact that inhibition was prevented by the presence of DTT and by NEM-modification indicated that it depended on -SH oxidation. Although DTT is weakly lipid soluble at pH ~7.4 (see Results and (Rang, 2007; White, 1999; Zhang et al., 1991)), it does not cross the bilayer within in the duration of a bilayer experiment and is thus useful for studying the sidedness of the inhibitory interaction (Eager and Dulhunty, 1999). Since DTT in the *cis*, but not *trans*, solution prevented inhibition, the -S-S- was likely formed on the cytoplasmic side of the channel complex, or in a region accessible to the cytoplasmic solution. Other redox modifications such as S-glutathionylation or S-nitrosylation (Hidalgo and Donoso, 2008), or reactions involving reactive oxygen species produced by redox cycling of the daunorubicin quinone moiety (Menna et al., 2007; Minotti et al., 2004), would not be significant in our system because the substrates and/or necessary mitochondrial enzymes are not present in the SR vesicle preparation.

Curiously, although DTT in the *cis* solution prevented the inhibition of RyR2 with daunorubicin, addition of DTT to the *cis* solution after inhibition had been established failed to restore channel activity. There are numerous examples of DTT preventing disulphide formation but not reducing the disulphide (Eager et al., 1997)(Terentyev et al., 2008). This apparent contradiction is explained by the –S-S- groups becoming buried in the protein and inaccessible to the solution.

*CSQ2 as an anthracycline target.* The interaction between daunorubicin and RyR2 did not depend on CSQ2 because both the activation and inhibitory phases were seen when CSQ2 was either bound to RyR2 and after CSQ2 dissociation from RyR2. However CSQ2 did modify rate of activation and the extent of inhibition. We speculate that CSQ2 binding may cause a conformational change in the RyR2, exposing the daunorubicin activation site and allowing faster activation by daunorubicin. CSQ2 binding to junctin and/or triadin for example may induce secondary conformational changes in RyR2 which expose the daunorubicin binding site. The lesser inhibition of RyR2 in channels lacking CSQ2 could be explained if CSQ2 removal altered RyR2 structure in a manner that reduced the impact of disulphide formation on channel gating.

Daunorubicin binding to CSQ2 reduces its Ca<sup>2+</sup> binding capacity. As CSQ2 polymers have a higher Ca<sup>2+</sup> binding capacity than monomers or dimers, daunorubicin might prevent CSQ2 polymerization and thus lower its Ca<sup>2+</sup> binding capacity. However CSQ2 (in contrast to CSQ1) is monomeric at physiological ionic strength (~150 mM) and Ca<sup>2+</sup> concentrations (~1 mM) (Park et al., 2005; Wei et al., 2009). Thus the reduced Ca<sup>2+</sup> binding capacity is unlikely to be linked to polymerisation, but it could be associated with some unfolding of the monomer induced by daunorubicin binding.

*Effects of altered RyR2 activity on SR function and heart failure.* Anthracyclines cause severe disruption of SR Ca<sup>2+</sup> handling, depleting the SR of its Ca<sup>2+</sup> load and causing cytoplasmic Ca<sup>2+</sup>

overload (Holmberg and Williams, 1990; Shadle et al., 2000; Shan et al., 1996). The elevated cytoplasmic  $\text{Ca}^{2+}$  triggers delayed after depolarisations (DADs), tachycardia and arrhythmias which are symptomatic of acute anthracycline-induced cardiotoxicity and heart failure (Gyorke and Terentyev, 2008; Shan et al., 1996). Prolonged  $\text{Ca}^{2+}$  overload also leads to some of the chronic effects of anthracycline treatment and heart failure including cardiomyocyte apoptosis and necrosis (Jessup and Brozena, 2003; Kumar et al., 2001; Minotti et al., 2004; Nakayama et al., 2007; Zucchi and Ronca-Testoni, 1997).

Our results indicate that the RyR2-dependent contribution to disruption of  $\text{Ca}^{2+}$  handling by daunorubicin would depend on the accumulated concentration of the drug in the myocytes. Increased RyR2 activity with low concentrations would contribute to DADs and arrhythmia in the early acute phase of daunorubicin toxicity. The inhibitory phase would become apparent after longer exposures and with higher accumulated drug concentrations. Inhibition of RyR2 channels can also lead to ventricular fibrillation through the generation of early after-depolarizations (EADs) when the action potential is prolonged (Bers, 2002; Gomez and Richard, 2004). EADs occur when L-type  $\text{Ca}^{2+}$  channels inactivation is slowed as a result of reduced  $\text{Ca}^{2+}$  release through RyR2 and a consequently lower than normal cytoplasmic  $\text{Ca}^{2+}$  concentration (Bers, 2002). This is seen in heart failure when  $\text{Ca}^{2+}$  stores are depleted or with loss-of-function mutations in RyR2 (Gomez and Richard, 2004) and could occur during the inhibitory phase of daunorubicin action. The reduced  $\text{Ca}^{2+}$  binding capacity of CSQ2 in the presence of daunorubicin would further contribute to EADs, by reducing SR  $\text{Ca}^{2+}$  load and  $\text{Ca}^{2+}$  available for release. The extent that daunorubicin metabolites alter RyR2 function and contribute to the effects of the parent compound remains to be determined.

To conclude, we describe a biphasic modulation of single RyR2 channels by clinically relevant concentrations of daunorubicin. Channels are initially activated and then inhibited by the drug. We provide evidence that the activation is caused by a redox-independent interaction between daunorubicin and RyR2, while inhibition is due to the oxidation of thiol groups. Daunorubicin reduces the  $\text{Ca}^{2+}$  binding capacity of CSQ2 but this does not mediate the effects of daunorubicin on RyR2. Our study provides important new information on the functional consequences of anthracycline binding to two of its targets in the SR of cardiomyocytes which may help in the eventual design of anthracyclines that do not detrimentally alter  $\text{Ca}^{2+}$  signalling in the heart.

**ACKNOWLEDGEMENTS.** The authors are grateful to S Pace and J Stivala for assistance.

#### **AUTHORSHIP CONTRIBUTION**

**Participated in research design:** Hanna A.D., Beard N.A., Dulhunty A.F.

**Conducted experiments:** Hanna A.D., Beard N.A., Janzcura M., Cho E.

**Performed data analysis:** Hanna A.D., Beard N.A., Dulhunty A.F.

**Wrote or contributed to the writing of the manuscript:** Hanna A.D., Beard N.A., Dulhunty A.F.

## REFERENCES

- Abbott RE and Schachter D (1976) Impermeant maleimides. Oriented probes of erythrocyte membrane proteins. *J Biol Chem* **251**: 7176-7183.
- Abramson JJ, Buck E, Salama G, Casida JE and Pessah IN (1988) Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. *J Biol Chem* **263**: 18750-18758.
- Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T and Nagai R (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. *J Mol Cell Cardiol* **30**: 243-254.
- Beard NA, Casarotto MG, Wei L, Varsanyi M, Laver DR and Dulhunty AF (2005) Regulation of ryanodine receptors by calsequestrin: effect of high luminal Ca<sup>2+</sup> and phosphorylation. *Biophys J* **88**: 3444-3454.
- Beard NA, Sakowska MM, Dulhunty AF and Laver DR (2002) Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels. *Biophys J* **82**: 310-320.
- Beard NA, Wei L, Cheung SN, Kimura T, Varsanyi M and Dulhunty AF (2008) Phosphorylation of skeletal muscle calsequestrin enhances its Ca<sup>2+</sup> binding capacity and promotes its association with junctin. *Cell Calcium* **44**: 363-373.
- Bers DM (2002) Calcium and cardiac rhythms: physiological and pathophysiological. *Circ Res* **90**: 14-17.
- Brini M (2004) Ryanodine receptor defects in muscle genetic diseases. *Biochem Biophys Res Commun* **322**: 1245-1255.
- Charlier HA, Jr., Olson RD, Thornock CM, Mercer WK, Olson DR, Broyles TS, Muhlestein DJ, Larson CL, Cusack BJ and Shadle SE (2005) Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. *Mol Pharmacol* **67**: 1505-1512.



- Cleland WW (1964) Dithiothreitol, a New Protective Reagent for Sh Groups. *Biochemistry* **3**: 480-482.
- Copello JA, Barg S, Onoue H and Fleischer S (1997) Heterogeneity of Ca<sup>2+</sup> gating of skeletal muscle and cardiac ryanodine receptors. *Biophys J* **73**: 141-156.
- Dulhunty AF, Laver DR, Gallant EM, Casarotto MG, Pace SM and Curtis S (1999) Activation and inhibition of skeletal RyR channels by a part of the skeletal DHPR II-III loop: effects of DHPR Ser687 and FKBP12. *Biophys J* **77**: 189-203.
- Dulhunty AF, Pouliquin P, Coggan M, Gage PW and Board PG (2005) A recently identified member of the glutathione transferase structural family modifies cardiac RyR2 substate activity, coupled gating and activation by Ca<sup>2+</sup> and ATP. *Biochem J* **390**: 333-343.
- Eager KR and Dulhunty AF (1999) Cardiac ryanodine receptor activity is altered by oxidizing reagents in either the luminal or cytoplasmic solution. *J Membr Biol* **167**: 205-214.
- Eager KR, Roden LD and Dulhunty AF (1997) Actions of sulfhydryl reagents on single ryanodine receptor Ca<sup>2+</sup>-release channels from sheep myocardium. *Am J Physiol* **272**: C1908-1918.
- Feng W, Liu G, Xia R, Abramson JJ and Pessah IN (1999) Site-selective modification of hyperreactive cysteines of ryanodine receptor complex by quinones. *Mol Pharmacol* **55**: 821-831.
- Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS and Olson RD (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. *Biochem Biophys Res Commun* **291**: 433-438.
- Gomez AM and Richard S (2004) Mutant cardiac ryanodine receptors and ventricular arrhythmias: is 'gain-of-function' obligatory? *Cardiovasc Res* **64**: 3-5.
- Gyorke S and Terentyev D (2008) Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. *Cardiovasc Res* **77**: 245-255.

- Hidalgo C and Donoso P (2008) Crosstalk between calcium and redox signaling: from molecular mechanisms to health implications. *Antioxid Redox Signal* **10**: 1275-1312.
- Holmberg SR and Williams AJ (1990) Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. *Circ Res* **67**: 272-283.
- Jalilian C, Gallant EM, Board PG and Dulhunty AF (2008) Redox potential and the response of cardiac ryanodine receptors to CLIC-2, a member of the glutathione S-transferase structural family. *Antioxid Redox Signal* **10**: 1675-1686.
- Jessup M and Brozena S (2003) Heart failure. *N Engl J Med* **348**: 2007-2018.
- Kim E, Tam M, Siems WF and Kang C (2005) Effects of drugs with muscle-related side effects and affinity for calsequestrin on the calcium regulatory function of sarcoplasmic reticulum microsomes. *Mol Pharmacol* **68**: 1708-1715.
- Kim E, Youn B, Kemper L, Campbell C, Milting H, Varsanyi M and Kang C (2007) Characterization of human cardiac calsequestrin and its deleterious mutants. *J Mol Biol* **373**: 1047-1057.
- Kumar D, Kirshenbaum LA, Li T, Danelisen I and Singal PK (2001) Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. *Antioxid Redox Signal* **3**: 135-145.
- Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D and Eldar M (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. *Am J Hum Genet* **69**: 1378-1384.
- Laver DR, Roden LD, Ahern GP, Eager KR, Junankar PR and Dulhunty AF (1995) Cytoplasmic Ca<sup>2+</sup> inhibits the ryanodine receptor from cardiac muscle. *J Membr Biol* **147**: 7-22.
- Marengo JJ, Hidalgo C and Bull R (1998) Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells. *Biophys J* **74**: 1263-1277.

- Marinov BS, Olojo RO, Xia R and Abramson JJ (2007) Non-thiol reagents regulate ryanodine receptor function by redox interactions that modify reactive thiols. *Antioxid Redox Signal* **9**: 609-621.
- Maruyama K, Mikawa T and Ebashi S (1984) Detection of calcium binding proteins by <sup>45</sup>Ca autoradiography on nitrocellulose membrane after sodium dodecyl sulfate gel electrophoresis. *J Biochem* **95**: 511-519.
- Menna P, Minotti G and Salvatorelli E (2007) In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. *Cell Biol Toxicol* **23**: 49-62.
- Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Jr., Ruccione K, Smithson WA and Robison LL (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. *J Clin Oncol* **19**: 3163-3172.
- Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* **56**: 185-229.
- Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR and Molkentin JD (2007) Ca<sup>2+</sup>- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. *J Clin Invest* **117**: 2431-2444.
- Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ, Jr. and Cusack BJ (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. *Toxicol Appl Pharmacol* **169**: 168-176.
- Ondrias K, Borgatta L, Kim DH and Ehrlich BE (1990) Biphasic effects of doxorubicin on the calcium release channel from sarcoplasmic reticulum of cardiac muscle. *Circ Res* **67**: 1167-1174.

- Park IY, Kim EJ, Park H, Fields K, Dunker AK and Kang C (2005) Interaction between cardiac calsequestrin and drugs with known cardiotoxicity. *Mol Pharmacol* **67**: 97-104.
- Pessah IN, Durie EL, Schiedt MJ and Zimanyi I (1990) Anthraquinone-sensitized Ca<sup>2+</sup> release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. *Mol Pharmacol* **37**: 503-514.
- Pessah IN, Kim KH and Feng W (2002) Redox sensing properties of the ryanodine receptor complex. *Front Biosci* **7**: a72-79.
- Rang HP (2007) *Rang and Dale's Pharmacology* Elsevier, Philadelphia.
- Sagara Y and Inesi G (1991) Inhibition of the sarcoplasmic reticulum Ca<sup>2+</sup> transport ATPase by thapsigargin at subnanomolar concentrations. *J Biol Chem* **266**: 13503-13506.
- Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS and Olson RD (2000) Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. *Biochem Pharmacol* **60**: 1435-1444.
- Shan K, Lincoff AM and Young JB (1996) Anthracycline-induced cardiotoxicity. *Ann Intern Med* **125**: 47-58.
- Terentyev D, Gyorke I, Belevych AE, Terentyeva R, Sridhar A, Nishijima Y, de Blanco EC, Khanna S, Sen CK, Cardounel AJ, Carnes CA and Gyorke S (2008) Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca<sup>2+</sup> leak in chronic heart failure. *Circ Res* **103**: 1466-1472.
- Wei L, Hanna AD, Beard NA and Dulhunty AF (2009) Unique isoform-specific properties of calsequestrin in the heart and skeletal muscle. *Cell Calcium* **45**: 474-484.
- White M (1999) *Principles of Pharmacokinetics, in Clinical Pharmacology for Anaesthetists*. Harcourt Publishers, London.
- Zhang N, Schuchmann HP and Sonntag CV (1991) The reaction of superoxide radical anion with dithiothreitol: a chain process. *J Physical Chem* **95**: 4718 - 4722.

Zucchi R and Ronca-Testoni S (1997) The sarcoplasmic reticulum Ca<sup>2+</sup> channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. *Pharmacol Rev* **49**: 1-51.

## Footnotes

\* these authors made equal senior author contributions to the work

This work was supported by the National Health and Medical Research Council [Grants 471400, 1003985].

## **FIGURE LEGENDS**

**Figure 1. Measurement of  $\text{Ca}^{2+}$  release from cardiac SR vesicles.** The recordings show optical density as a function of time after vesicle addition during a  $\text{Ca}^{2+}$  release experiment. An increase in optical density indicates an increase in extravesicular  $[\text{Ca}^{2+}]$  detected by antipyrylazo III absorbance at 710nm. Cardiac SR vesicles were first added to the cuvette.  $[\text{Ca}^{2+}]$  increased with vesicle addition and then fell as  $\text{Ca}^{2+}$  was taken up into the vesicles upon activation of SERCA. The SR was then loaded with four additions of  $7.5 \mu\text{M}$   $\text{Ca}^{2+}$ . Thapsigargin ( $300 \text{ nM}$ ) was added to block SERCA, and then  $100 \mu\text{M}$  daunorubicin in **A** or  $5 \text{ mM}$  caffeine in **B** to stimulate  $\text{Ca}^{2+}$  release. Ruthenium red was then added followed by the  $\text{Ca}^{2+}$  ionophore which allowed  $\text{Ca}^{2+}$  remaining in the vesicles to equilibrate with the extravesicular solution. The final large increase in  $[\text{Ca}^{2+}]$  with ionophore indicates (a) that  $\text{Ca}^{2+}$  had not been maximally released from the vesicles and (b) the antipyrylazo response was not saturated. The arrows at the end of each trace indicate the total amount of  $\text{Ca}^{2+}$  released from the level at the time of thapsigargin addition (broken line) to the maximum release after ionophore addition. The total release is also indicative of the total amount accumulated by the SR. In **A**, the immediate effect of daunorubicin on  $\text{Ca}^{2+}$  release was measured. In **B**, the effect of 30 min incubation in daunorubicin on caffeine-induced  $\text{Ca}^{2+}$  release was evaluated. The shaded areas in **A** and **B** encircle the regions of the experiment shown in Fig 2A and Figs 2C & 2D respectively.

**Figure 2. Effects of daunorubicin on  $\text{Ca}^{2+}$  release from cardiac SR.** **A)** Daunorubicin added at concentrations of  $\geq 50 \mu\text{M}$  (using the protocol in Fig. 1A), had an immediate action in increasing the rate of  $\text{Ca}^{2+}$  release. Daunorubicin concentration is shown to the left of each trace and the initial rate of  $\text{Ca}^{2+}$  release is shown to the right. **B)** Average rates of  $\text{Ca}^{2+}$  release with indicated concentration of daunorubicin. Note the comments in the text regarding the intentionally high daunorubicin concentrations used to evoke an immediate effect of daunorubicin addition. The inset in **B** shows the average initial rates of  $\text{Ca}^{2+}$  release (open circles)

and the rate of  $\text{Ca}^{2+}$  release measured 10 min (closed circles) after addition of vehicle (0  $\mu\text{M}$  daunorubicin) or 10  $\mu\text{M}$  daunorubicin in one set of experiments in which daunorubicin-induced release was monitored for ~11 min. **(C & D)** Caffeine-induced  $\text{Ca}^{2+}$  release from vesicles equilibrated for ~30 min in daunorubicin (20 min before the start of the experiment plus an additional 10 min during the  $\text{Ca}^{2+}$  loading steps). Daunorubicin concentration is shown to the left of each trace. **C)** Records showing the effect of equilibrating SR vesicles in 10 to 50 nM daunorubicin on caffeine-induced  $\text{Ca}^{2+}$  release. **D)** Records showing the effect of equilibrating SR vesicles 0.1 to 10  $\mu\text{M}$  daunorubicin on caffeine-induced  $\text{Ca}^{2+}$  release. **E)** Average relative rates of  $\text{Ca}^{2+}$  release after addition of thapsigargin (grey symbols) and caffeine-induced  $\text{Ca}^{2+}$  release (black symbols) after incubation with indicated concentrations of daunorubicin. The dotted lines under the records in **A, C and D** indicate the slopes used in determining the rates of release shown in **B** and **E**. The asterisks (\*) indicate a significant difference from the control rates of release measured in the absence of daunorubicin ( $n = 5$  for all concentrations). In **E**, the asterisks (\*) over data obtained after incubation with of 5 and 10 nM daunorubicin indicate a significant difference in caffeine-induced  $\text{Ca}^{2+}$  release only.

**Figure 3. The activity of RyR2 is modified by daunorubicin.** **A) & B)** 3s traces of native RyR2 channel activity at +40mV. Channels open upward from zero current (c, continuous line) to maximum open conductance (o, broken line). **(A)** *Top panel* – Control recording; *middle and bottom panel* – after the addition of 1  $\mu\text{M}$  daunorubicin to the *trans* chamber, maximal RyR2 activity was measured at 11 min in this channel, with no further change in activity recorded for 20 min after daunorubicin addition. **(B)** *Top panel* – Control recording from different native RyR2 channel; *middle and bottom panel* – after the addition of 10  $\mu\text{M}$  daunorubicin to the *trans* chamber, maximal RyR2 activation was measured at 8 min, and maximal RyR2 inhibition was recorded 16 min after daunorubicin addition. **(C) & D)**  $P_o$  was measured every 10s throughout



experiments with 1  $\mu\text{M}$  daunorubicin (**C**) or 2.5  $\mu\text{M}$  daunorubicin in (**D**) at +40 mV (dark grey bins) and -40 mV (light grey bins). **E** & **F**) Combined data from measurements of  $P_o$  at +40 mV and -40 mV ( $n = 8 - 12$  at each concentration). Data is presented as average relative  $P_o$  (log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oC}$  (see Methods). Average relative  $P_o$  during the activation phase is shown in **E**) and average relative  $P_o$  during the inhibitory phase shown in **F**). The asterisk (\*) indicates a significance difference from the control  $P_o$  recorded before adding daunorubicin. The (#) indicates a significant difference between  $P_o$  during the activation and inhibitory phase.

**Figure 4. Daunorubicin-induced activation is reversible upon washout.** **A**) & **C**) 3s traces of native RyR2 channel activity at +40mV. Channels open upward from zero current (c, continuous line) to maximum open conductance (o, broken line). **A**) *Top panel* – Control recording; *middle panel* – after the addition of 1  $\mu\text{M}$  daunorubicin to the *trans* chamber, maximal activity was measured (8 min after daunorubicin addition); *bottom panel* –after the *trans* chamber was perfused with control recording solution. **C**) *Top panel* – Control recording; *middle panel* – after the addition of 2.5  $\mu\text{M}$  daunorubicin to the *trans* chamber, maximal RyR2 inhibition was measured (14 min after daunorubicin addition) ; *bottom panel* – washout, after the *trans* chamber was perfused with control solution. **B**) & **D**) Combined data from measurements of  $P_o$  at +40 mV and -40 mV ( $n = 9$  in **B**;  $n = 12$  in **D**). Average  $P_o$  before daunorubicin addition, during the activation phase with 1  $\mu\text{M}$  daunorubicin and then after washout of 1  $\mu\text{M}$  daunorubicin are shown in **B**). Average relative  $P_o$  before daunorubicin addition, during the inhibitory phase with 2.5  $\mu\text{M}$  daunorubicin and then after washout of 2.5  $\mu\text{M}$  daunorubicin are shown in **D**). The asterisk (\*) indicates a significance difference from the control  $P_o$  recorded before adding daunorubicin. The (#) indicates a significant difference between  $P_o$  in the presence of daunorubicin and after daunorubicin washout. **E**) Western blot showing RyR2 bound to CNBr-activated sepharose (lane 1) and to daunorubicin coupled CNBr-activated sepharose (lane 2). **F**)

Average density of RyR2 of control (bin 1) and daunorubicin coupled CNBr-activated sepharose (bin 2). Results are from three experiments, including one where RyR2 was pre-incubated with CNBr-activated sepharose. The asterisk (\*) indicates a significance difference in densitometry units between the control and daunorubicin coupled CNBr-activated sepharose.

**Figure 5. Effect of DTT in the *trans* solution on the action of daunorubicin –A) & C) 3s**

traces of native RyR2 channel activity at +40mV. Channels open upward from zero current (c, continuous line) to maximum open conductance (o, broken line). **A)** *I<sup>st</sup> panel* – control activity; *2<sup>nd</sup> panel* - addition of 1 mM DTT to the *trans* solution; *3<sup>rd</sup> and 4<sup>th</sup> panels* –10 min (*3<sup>rd</sup> panel*) and 25 min (*4<sup>th</sup> panel*) after the addition of 10  $\mu$ M daunorubicin to the *trans* solution. **C)** *I<sup>st</sup> panel* – Control activity; *2<sup>nd</sup> and 3<sup>rd</sup> panel* - 6 min (*2<sup>nd</sup> panel*) and 12 min (*3<sup>rd</sup> panel*) after the addition of 10  $\mu$ M daunorubicin to the *trans* solution; *4<sup>th</sup> panel* – after the addition of 1 mM DTT to the *trans* solution. **B)** & **D)** show average combined data for  $P_o$  at +40 mV and -40 mV (n = 14 in **B)** and n = 10 in **D)**). The asterisk (\*) indicates a significant difference from the control  $P_o$  recorded before adding daunorubicin. The (#) indicates a significant difference between  $P_o$  during the activation and inhibitory phase of daunorubicin action.

**Figure 6. Effect of DTT in the *cis* solution on the action of daunorubicin – A) & C) 3s traces**

of native RyR2 channel activity at +40mV. Channels open upward from zero current (c, continuous line) to maximum open conductance (o, broken line). **(A)** *I<sup>st</sup> panel* – control activity; *2<sup>nd</sup> panel* - after adding 1 mM DTT to the *cis* solution, *3<sup>rd</sup> and 4<sup>th</sup> panels* – 10 min (*3<sup>rd</sup> panel*) and 25 min (*4<sup>th</sup> panel*) after adding 10  $\mu$ M daunorubicin to the *cis* solution. **C)** *I<sup>st</sup> panel* – Control activity; *2<sup>nd</sup> and 3<sup>rd</sup> panel* - 5 min (*2<sup>nd</sup> panel*) and 13 min (*3<sup>rd</sup> panel*) after adding 10  $\mu$ M daunorubicin to the *cis* solution; *4<sup>th</sup> panel* – after adding 1 mM DTT to the *cis* solution. **B)** & **D)** show average combined data for  $P_o$  at +40 mV and -40 mV (n = 8 in **B)** and n = 10 in **D)**). The (#)

indicates a significant difference between  $P_o$  during the activation and inhibitory phase of daunorubicin action.

**Figure 7. Effect of NEM alkylation on the actions of daunorubicin.** A) to C) Combined data from measurements of  $P_o$  at +40 mV and -40 mV. The effect of NEM alone is shown in **A)** (n = 6). Data in **A)** is presented as average relative  $P_o$  (log rel  $P_o$ , i.e.  $\log_{10}P_{oN} - \log_{10}P_{oC}$ ):  $P_o$  in NEM relative to  $P_o$  before adding NEM (see Methods). The effect of adding 10  $\mu$ M daunorubicin after 9 min exposure to NEM is shown in **B)** and **C)** (n = 14). Data in **B)** is presented as  $P_o$  after adding daunorubicin relative to  $P_o$  at the start of the experiment before NEM addition (log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oC}$ ). Data in **C)** is presented as  $P_o$  after adding daunorubicin relative to  $P_o$  in NEM before daunorubicin addition (log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oN}$ ). Data in **D)** is presented as relative  $P_o$  after adding daunorubicin alone (relative to  $P_o$  prior to adding daunorubicin: log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oC}$ ), or  $P_o$  after adding daunorubicin in the presence of NEM (relative to  $P_o$  in NEM prior to adding daunorubicin: log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oN}$ ).

**Figure 8. Daunorubicin effects on RyR2 do not depend on CSQ2.** Combined data for  $P_o$  at -40mV and +40mV for native RyR2 channels (RyR2+CSQ2) (n = 13) and for RyR2 after dissociation of CSQ2 (RyR2-CSQ2) (n = 10). Data is presented as average relative  $P_o$  (log rel  $P_o$ , i.e.  $\log_{10}P_{oD} - \log_{10}P_{oC}$ ). The asterisk (\*) indicates a significant difference from control activity before adding daunorubicin. The (#) indicates a significant difference between  $P_o$  during the activation and inhibitory phases of daunorubicin action. The (@) indicates a significant difference between average  $P_o$  in native RyR2 and CSQ(-) RyR2 in the inhibitory phase.

## TABLES

**Table 1.** Time-dependent activation and inhibition of native RyR2 (containing CSQ2) and RyR2 after CSQ2 dissociation (CSQ(-) RyR2) by daunorubicin.

[Daunorubicin]	Time to activation phase (min)		Time to inhibition phase (min)	
	Native RyR2	CSQ(-) RyR2	Native RyR2	CSQ(-) RyR2
10 nM	15.0 ± 4.0	-	-	-
500 nM	7.9 ± 2.5	-	-	-
1 μM	8.1 ± 2.0	-	-	-
2.5 μM	3.0 ± 3.3	11.1 ± 1.3*	12.6 ± 4.3	17.6 ± 0.7
10 μM	4.0 ± 1.1	-	11.5 ± 1.9	-

Asterisk (\*) indicates a significant difference between time to activation in native RyR2 (containing CSQ2) and RyR2 channels lacking CSQ2 (CSQ(-)RyR2). Dash (-) indicates daunorubicin concentrations not tested.

**Table 2.**  $\text{Ca}^{2+}$  binding capacity of CSQ2 in the presence and absence of 2.5  $\mu\text{M}$  daunorubicin.

[ $\text{Ca}^{2+}$ ] mM	$\text{Ca}^{2+}$ binding capacity (nmol $\text{Ca}^{2+}$ /mg purified CSQ2)	
	No daunorubicin	2.5 $\mu\text{M}$ daunorubicin
0.1	131 $\pm$ 15	97 $\pm$ 9 *
1.0	168 $\pm$ 16	120 $\pm$ 11 *
1.5	194 $\pm$ 19	134 $\pm$ 14 *

Asterisk (\*) indicates a significant difference between  $\text{Ca}^{2+}$  binding capacity of CSQ2 in the presence and absence of 2.5  $\mu\text{M}$  daunorubicin (n=8-16).

Figure 1




Figure 2




Figure 3






Figure 4




Figure 5




Figure 6







Figure 7




Figure 8

